Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.59 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19234502 | 0.88 | CRHBP (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL24324831 | 0.86 | SPHK1 (0.61) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL19375764 | 0.83 | SPHK1 (0.49) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL20715718 | 0.82 | GAA (0.55) | SPHK1SPHK2 | |
| SCHEMBL21206985 | 0.81 | SPHK1 (0.59) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL21724243 | 0.80 | LTA4H (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL21724241 | 0.80 | LTA4H (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL24324832 | 0.79 | SPHK1 (0.64) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL6291030 | 0.78 | LTA4H (0.45) | SPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL14349974 | 0.78 | SPHK1 (0.56) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | SPHK1 405/4885SPHK2 366/4885S1PR1 174/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | SPHK1 405/4885SPHK2 366/4885S1PR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.